{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:42:01Z","timestamp":1787164921898,"version":"build-2736575974"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"\n Importance<\/jats:title>\n Localized melanomas account for the highest proportion of melanoma deaths; however, few studies have assessed factors associated with risk of recurrence of localized melanomas.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine the clinical and pathologic factors associated with the risk of melanoma recurrence for localized (stage IA to IIC) melanomas.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Results of this study suggest that factors in addition to melanoma ulceration and thickness provide an important guide for patient surveillance and counseling about potential recurrence. Participants were individuals diagnosed with stage IA to IIC melanomas from 2010 to 2017. Patients with more than 1 melanoma diagnosed during this time frame, whose index melanomas were recurrences, and whose melanomas were noncutaneous were excluded (125 melanomas). Data were analyzed from January 1 to March 15, 2025.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The presence or absence of melanoma recurrence and time to melanoma recurrence.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In 1092 patients with melanoma diagnosed from 2010 to 2017, the median age at the time of diagnosis was 60 (range, 0-96) years; most patients were male (57.0% [622]); race and ethnicity categories were Hispanic (4.1% [45]), non-Hispanic (94.4% [1031]), White (96.7% [1056]), other (3.3% [36]), and unknown (1.5% [16]). Multivariable analysis identified 6 variables significantly associated with time to recurrence: ulceration (hazard ratio [HR], 3.48; 95% CI, 2.51-4.82;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), thickness (HR, 1.09; 95% CI, 1.05-1.13;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), tumor location on the scalp or neck (HR, 3.22; 95% CI, 1.94-5.37;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) or face (HR, 2.14; 95% CI, 1.29-3.53;\n P<\/jats:italic>\n \u2009=\u2009.003) compared with the arms, neurotropism (HR, 1.96; 95% CI, 1.03-3.72;\n P<\/jats:italic>\n \u2009=\u2009.04), lymphovascular invasion (HR, 2.52; 95% CI, 1.00-6.34;\n P<\/jats:italic>\n \u2009=\u2009.049), and mitoses (HR, 3.93; 95% CI, 2.47-6.26;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this study, for localized melanomas, variables beyond those currently considered standard for staging for survival prognosis were associated with time to melanoma recurrence; consideration of factors beyond thickness and ulceration could be valuable in helping to guide surveillance for recurrences.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2026.0001","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:30:37Z","timestamp":1772641837000},"page":"378","source":"Crossref","is-referenced-by-count":3,"title":["Clinical and Pathologic Factors in Stage I and II Melanoma Recurrence"],"prefix":"10.1001","volume":"162","author":[{"given":"Maya","family":"Mundada","sequence":"first","affiliation":[{"name":"School of Medicine, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Zhong","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"So","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Grimes","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"McGuire","sequence":"additional","affiliation":[{"name":"Helen Diller Comprehensive Cancer Center, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Griffin","sequence":"additional","affiliation":[{"name":"Helen Diller Comprehensive Cancer Center, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Wei","sequence":"additional","affiliation":[{"name":"Helen Diller Comprehensive Cancer Center, University of California, San Francisco"},{"name":"Department of Dermatology, University of California, San Francisco"},{"name":"Dermatology Service, San Francisco VA Health Care System, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"doi260001r2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global burden of cutaneous melanoma in 2020 and projections to 2040.","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi260001r3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv294","article-title":"Melanoma thickness and survival trends in the United States, 1989 to 2009.","volume":"108","author":"Shaikh","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"92","key":"doi260001r4","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2017.12.024","article-title":"Trends in incidence of thick, thin and in situ melanoma in Europe.","volume":"92","author":"Sacchetto","year":"2018","journal-title":"Eur J Cancer"},{"issue":"5","key":"doi260001r5","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1001\/jamaoncol.2022.0134","article-title":"Differences in thickness-specific incidence and factors associated with cutaneous melanoma in the US from 2010 to 2018.","volume":"8","author":"Chen","year":"2022","journal-title":"JAMA Oncol"},{"issue":"4","key":"doi260001r6","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/jid.2014.452","article-title":"More people die from thin melanomas (?1?mm) than from thick melanomas (>4?mm) in Queensland, Australia.","volume":"135","author":"Whiteman","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"2","key":"doi260001r7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jaad.2016.10.018","article-title":"Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992-2013.","volume":"76","author":"Landow","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"doi260001r8","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1001\/jamadermatol.2023.3256","article-title":"Stage-specific risk of recurrence and death from melanoma in Denmark, 2008-2021: a national observational cohort study of 25?720 patients with stage IA to IV melanoma.","volume":"159","author":"Helvind","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi260001r9","doi-asserted-by":"publisher","first-page":"5641","DOI":"10.1038\/s41598-023-32434-6","article-title":"Epidemiological and clinical characterization of a population-based cohort of cutaneous malignant melanoma patients in the South Region of Portugal.","volume":"13","author":"Alves da Costa","year":"2023","journal-title":"Sci Rep"},{"issue":"6","key":"doi260001r10","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1001\/jamadermatol.2019.0440","article-title":"Risk of melanoma recurrence after diagnosis of a high-risk primary tumor.","volume":"155","author":"von Schuckmann","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi260001r11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2010.09.772","article-title":"Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry.","volume":"66","author":"Leiter","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"doi260001r12","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"doi260001r13","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.11S1a162S","article-title":"Melanoma: staging and follow-up.","volume":"11","author":"Papageorgiou","year":"2021","journal-title":"Dermatol Pract Concept"},{"issue":"2","key":"doi260001r14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jaad.2018.02.059","article-title":"Patients prioritize local recurrence risk over other attributes for surgical treatment of facial melanomas-Results of a stated preference survey and choice-based conjoint analysis.","volume":"79","author":"Etzkorn","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"doi260001r15","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1245\/s10434-019-07369-w","article-title":"Recurrence of melanoma after a negative sentinel node biopsy: predictors and impact of recurrence site on SURVIVAL.","volume":"26","author":"Thomas","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"doi260001r16","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1001\/jamasurg.2013.1335","article-title":"Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result.","volume":"148","author":"Jones","year":"2013","journal-title":"JAMA Surg"},{"issue":"9","key":"doi260001r17","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1111\/jdv.14280","article-title":"Prognostic risk factors of first recurrence in patients with primary stages I-II cutaneous malignant melanoma - from the population-based Swedish melanoma register.","volume":"31","author":"Lyth","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"doi260001r18","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.surg.2015.12.002","article-title":"Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes.","volume":"159","author":"Egger","year":"2016","journal-title":"Surgery"},{"issue":"12","key":"doi260001r19","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1002\/ijc.30407","article-title":"Epidemiology of cutaneous melanoma in Sweden-Stage-specific survival and rate of recurrence.","volume":"139","author":"Rockberg","year":"2016","journal-title":"Int J Cancer"},{"issue":"1","key":"doi260001r20","doi-asserted-by":"publisher","first-page":"21012","DOI":"10.1038\/s41598-021-00386-4","article-title":"Risk factors of recurrence and distant metastasis in primary cutaneous melanoma in Taiwan.","volume":"11","author":"Lee","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"doi260001r21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41698-022-00321-4","article-title":"Prediction of early-stage melanoma recurrence using clinical and histopathologic features.","volume":"6","author":"Wan","year":"2022","journal-title":"NPJ Precis Oncol"},{"issue":"4","key":"doi260001r22","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jaad.2019.09.029","article-title":"Male sex and Breslow thickness are important risk factors for recurrence of localized melanoma in Korean populations.","volume":"83","author":"Oh","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"doi260001r23","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1097\/JCMA.0000000000000586","article-title":"Factors influencing locoregional recurrence and distant metastasis in Asian patients with cutaneous melanoma after surgery: a retrospective analysis in a tertiary hospital in Taiwan.","volume":"84","author":"Chu","year":"2021","journal-title":"J Chin Med Assoc"},{"issue":"1","key":"doi260001r24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/CMR.0000000000000302","article-title":"Prospective evaluation of prognostic indicators for early recurrence of cutaneous melanoma.","volume":"27","author":"Matheson","year":"2017","journal-title":"Melanoma Res"},{"issue":"4","key":"doi260001r25","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/01.sla.0000090446.63327.40","article-title":"Thin melanomas: predictive lethal characteristics from a 30-year clinical experience.","volume":"238","author":"Kalady","year":"2003","journal-title":"Ann Surg"},{"issue":"6","key":"doi260001r26","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/1097-0142(19850315)55:6<1398::AID-CNCR2820550639>3.0.CO;2-A","article-title":"The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma.","volume":"55","author":"Urist","year":"1985","journal-title":"Cancer"},{"issue":"9","key":"doi260001r27","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1002\/cam4.2252","article-title":"Melanoma incidence, recurrence, and mortality in an integrated healthcare system: a retrospective cohort study.","volume":"8","author":"Feigelson","year":"2019","journal-title":"Cancer Med"},{"issue":"3","key":"doi260001r28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00403-021-02229-8","article-title":"Risk factors and patterns of recurrence after sentinel lymph node biopsy for thin melanoma.","volume":"314","author":"Kim","year":"2022","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"doi260001r29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213475","article-title":"Local recurrence and metastasis in patients with malignant melanomas after surgery: a single-center analysis of 202 patients in South Korea.","volume":"14","author":"Cho","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"doi260001r30","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.amjsurg.2011.06.048","article-title":"Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker.","volume":"202","author":"Callender","year":"2011","journal-title":"Am J Surg"},{"issue":"9","key":"doi260001r31","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1177\/000313481708300934","article-title":"Tumor mitotic rate and association with recurrence in sentinel lymph node negative Stage II melanoma patients.","volume":"83","author":"Laks","year":"2017","journal-title":"Am Surg"},{"issue":"4","key":"doi260001r32","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/DSS.0000000000003699","article-title":"Local recurrence rates after excision of desmoplastic melanoma: a systematic review and meta-analysis.","volume":"49","author":"Ran","year":"2023","journal-title":"Dermatol Surg"},{"issue":"6","key":"doi260001r33","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/jamadermatol.2023.0620","article-title":"Association of excision margin size with local recurrence and survival in patients with T1a melanoma at critical structures.","volume":"159","author":"Maurichi","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"4","key":"doi260001r34","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/ijd.15939","article-title":"Different mitotic rates are associated with different prognostic factors, relapses, and survival rates in melanoma.","volume":"61","author":"Tas","year":"2022","journal-title":"Int J Dermatol"},{"issue":"2","key":"doi260001r35","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jaad.2022.01.040","article-title":"The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultrathick melanomas (=15 mm in thickness).","volume":"87","author":"El Sharouni","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi260001r36","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/BF02305762","article-title":"Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial.","volume":"3","author":"Karakousis","year":"1996","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"doi260001r37","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.ejso.2016.03.038","article-title":"Worse outcome for patients with recurrent melanoma after negative sentinel lymph biopsy as compared to sentinel-positive patients.","volume":"42","author":"Gambichler","year":"2016","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"doi260001r39","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1245\/s10434-017-6267-7","article-title":"Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update.","volume":"25","author":"Wong","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"21","key":"doi260001r40","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1002\/cncr.33088","article-title":"Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system.","volume":"126","author":"Kashani-Sabet","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"doi260001r41","doi-asserted-by":"crossref","first-page":"MMT12","DOI":"10.2217\/mmt-2019-0003","article-title":"Surveillance imaging for metastasis in high-risk melanoma: importance in individualized patient care and survivorship.","volume":"6","author":"Freeman","year":"2019","journal-title":"Melanoma Manag"},{"issue":"3","key":"doi260001r42","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/jso.70035","article-title":"Validation of a clinicopathologic and gene expression model for predicting sentinel node metastasis in melanoma: a multicenter Danish cohort study.","volume":"132","author":"Weitemeyer","year":"2025","journal-title":"J Surg Oncol"},{"issue":"1","key":"doi260001r43","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12957-024-03512-4","article-title":"Integrating the melanoma 31-gene expression profile test with clinical and pathologic features can provide personalized precision estimates for sentinel lymph node positivity: an independent performance cohort.","volume":"22","author":"Kriza","year":"2024","journal-title":"World J Surg Oncol"},{"issue":"9","key":"doi260001r44","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1001\/jamadermatol.2020.1729","article-title":"Prognostic gene expression profiling in cutaneous melanoma: identifying the knowledge gaps and assessing the clinical benefit.","volume":"156","author":"Grossman","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"11","key":"doi260001r45","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1200\/JCO.20.02446","article-title":"Development and validation of nomograms to predict local, regional, and distant recurrence in patients with thin (T1) melanomas.","volume":"39","author":"El Sharouni","year":"2021","journal-title":"J Clin Oncol"},{"key":"doi260001r46","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jdin.2022.08.014","article-title":"The impact of stage-related features in melanoma recurrence prediction: a machine learning approach.","volume":"10","author":"Wan","year":"2022","journal-title":"JAAD Int"},{"issue":"2","key":"doi260001r47","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jaad.2023.08.105","article-title":"Development and validation of time-to-event models to predict metastatic recurrence of localized cutaneous melanoma.","volume":"90","author":"Wan","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"doi260001r1","unstructured":"American Cancer Society. Key statistics for melanoma skin cancer. American Cancer Society. January 16, 2025. Accessed August 1, 2025. https:\/\/www.cancer.org\/cancer\/types\/melanoma-skin-cancer\/about\/key-statistics.html"},{"key":"doi260001r38","unstructured":"NCCN Clinical Practice Guidelines in Oncology - Melanoma. Cutaneous. Published online January 28, 2025. Accessed July 21, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2845561\/jamadermatology_mundada_2026_oi_260001_1775760778.61407.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T15:00:32Z","timestamp":1776265232000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2845561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.0001","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}